As the United States moves to end longstanding commitments to global health co-operation—punctuated by its withdrawal from the WHO—a new report offers guidance on how Canada can strategically position itself in this fast-changing context.
Patients using icodec tend to have a higher incidence of hypoglycemic events compared to glargine or degludec, especially on days 2–4 of the weekly dosing cycle.